Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

(2012) A. Tefferi   BLOOD

Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?

(2012) Claire Harrison et al.   BRITISH JOURNAL OF HAEMATOLOGY

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

(2012) Rita Andraos et al.   Cancer Discovery

Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software

(2011) Lee Kamentsky et al.   BIOINFORMATICS

Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors

(2011) Claude Haan et al.   CHEMISTRY & BIOLOGY

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Companies hope for kinase inhibitor JAKpot

(2011) Elie Dolgin   NATURE REVIEWS DRUG DISCOVERY

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

(2011) Alfonso Quintás-Cardama et al.   NATURE REVIEWS DRUG DISCOVERY

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

(2011) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6

(2010) Jill E. Chrencik et al.   JOURNAL OF MOLECULAR BIOLOGY

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains

(2009) Neal K. Williams et al.   JOURNAL OF MOLECULAR BIOLOGY

How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis

(2009) Alessandro M. Vannucchi   LEUKEMIA RESEARCH

Inhibitor hijacking of Akt activation

(2009) Tatsuya Okuzumi et al.   Nature Chemical Biology

PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity

(2009) Angus J M Cameron et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling

(2009) S Haan et al.   ONCOGENE

Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain

(2009) Troii Hall et al.   PROTEIN EXPRESSION AND PURIFICATION

Aberrant signal transduction pathways in myeloproliferative neoplasms

(2008) J Kota et al.   LEUKEMIA